(4) Ketogenic diet, high - intensity interval training (HIIT), and memory training in
the treatment of mild cognitive impairment: A case study.
Learn about the causes, symptoms and
treatment of mild cognitive impairment.
4) Montgomery SA, Thal LJ, Amrein, R. Meta - analysis of double blind randomized controlled clinical trials of acetyl - L - carnitine versus placebo in
the treatment of mild cognitive impairment and mild Alzheimer's disease.
A $ 2.4 million, 12 - week phase 1 trial testing the safety and tolerability of the steroid allopregnanolone for
treatment of mild cognitive impairment and Alzheimer's, led by Roberta Brinton and Lon Schneider of the University of Southern California in Los Angeles.
Not exact matches
The first - line
treatment for the majority
of separation anxiety cases is psychotherapy;
cognitive behavioral therapy in particular is used with great success on
mild to moderate cases.
Researchers estimate that as many as 2.1 million patients with
mild cognitive impairment could develop Alzheimer's dementia over a two - decade period while waiting for evaluation and
treatment resources after approval
of an Alzheimer's disease - modifying therapy by the federal Food and Drug Administration.
The accelerated rate
of brain atrophy in elderly with
mild cognitive impairment can be slowed by
treatment with homocysteine - lowering B vitamins.
We show that a simple and safe
treatment that targets homocysteine can slow down the accelerated rate
of brain atrophy found in
mild cognitive impairment.
The operationalization
of mild cognitive impairment (MCI) led to targeting earlier symptomatic cases
of the illness and
treatment strategies based less on pathology and more on a chance to halt or slow decline than there would be earlier in the disease.1 With the development
of amyloid imaging, MCI due to AD diagnosis was refined, 2 and early - stage AD was extended further to include preclinical AD, 3 wherein a positive amyloid positron emission tomography (PET) scan or diagnostic low levels
of cerebrospinal fluid β - amyloid (Aβ) indicated the presence
of pathology in people who were cognitively normal.
His group has developed a new approach to the
treatment of Alzheimer's disease, and this approach has led to the discovery
of subtypes
of Alzheimer's disease, followed by the first description
of reversal
of symptoms in patients with
mild cognitive impairment and early Alzheimer's disease, with the ReCODE (Reversal of Cognitive Decline)
cognitive impairment and early Alzheimer's disease, with the ReCODE (Reversal
of Cognitive Decline)
Cognitive Decline) protocol.
As HGH levels were increased in otherwise healthy adults and those who were in the beginning stages
of mild cognitive impairment and Alzheimer's disease,
treatment began to ameliorate their
cognitive declines as measured by numerous tests described in the Neurobiology
of Aging in 2006.